Navigation Links
Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
Date:4/20/2011

SAN DIEGO, April 20, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection. Through the collaboration with the University of Minnesota and James Cloyd, PharmD; Neurelis has partnered with the leading experts in clinical research of the nasal delivery of benzodiazepines.  Results from this important study are expected in June.

"We are pleased to work with Dr. Cloyd and the University of Minnesota to complete dosing in the first human trial of our unique nasally administered formulations of diazepam," stated David Hale, Chairman.  "Neurelis has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures.  These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits."

Intranasal diazepam is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute breakthrough seizure activity. There are over 2.7 million people with epilepsy in the United States.  It is estimated that between 30% to 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

Presently, there is only one product approved for the treatment of acute repetitive seizures outside of the acute care setting, which is a rectally administered formulation of diazepam called Diastat®.  Because of its rect
'/>"/>

SOURCE Neurelis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , September 18, 2014 ... Markets ( http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition ... Business Report"  report to their offering.  ... analyzes the worldwide markets for Sugar Alcohols ... Segments: Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
... Vascular Disrupting Agent and,Tubulin Inhibitor , SALT ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced ... mode of action of its,investigational new drug, ... annual meeting of the American Association for ...
... 18, 2007 - Gemin,X today announced the presentation ... lead compound, GX15-070 (obatoclax), in infant,acute lymphoblastic leukemia ... at the Annual Meeting of the American Association,for ... potent single agent activity against ALL blast cells,and ...
Cached Medicine Technology:Myriad Genetics Presents Azixa's Mode of Action at AACR 2Myriad Genetics Presents Azixa's Mode of Action at AACR 3Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3
(Date:9/19/2014)... New York (PRWEB) September 19, 2014 ... & Game Building Platform . Earlier this month Appy Pie ... Powerful Tools for the Aspiring App Developer' by Yahoo . ... which allows people to develop beautiful applications within minutes and ... development, With advanced features and support for latest mobile operating ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... escalated the fight against antibiotic-resistant bacteria on Thursday, ordering ... deal with the threat. Obama signed an ... charged with crafting a national action plan for dealing ... treatable bacteria that have become resistant to standard antibiotics ...
(Date:9/19/2014)... 2014 ShopRite has launched its new ... with the 2014-2015 school year. The new program will ... eBoxTops and special donations throughout the year. , Customers ... registering their ShopRite Price Plus Card at shopriteformyschool.com can ... favorite school. By using their Price Plus Club Card ...
(Date:9/19/2014)... September 19, 2014 The Translational ... new ND® Infusion Catheter is being used ... , The study commenced on September 4th, 2014 at ... of the new catheter demonstrated a number of advancements ... stem cells. “We are at the forefront of revolutionizing ...
(Date:9/19/2014)... QueenBeeTickets.com has the largest ticket inventory that online ... set to begin on January 21 of 2015, discount John ... secure website. , Click Here to view the ... , The Plain Spoken Tour has recently been announced, and ... a show coming to their local area. Presales have been ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2
... disease characterized by difficultly in breathing and the ... in these patients. Earlier research has shown that ... and endurance of respiratory muscles of COPD patients, ... found that this intense training// is difficult for ...
... of Texas has found a gene mutation in people with ... too much calcium. They reported on six gene mutations which ... much calcium absorption - a condition known as absorptive hypercalciuria ... a greater risk// for osteoporosis because of deficiencies in the ...
... hospitals to overcome illness. However, very often, patients land ... infections that they contract during their stay. Sanjay Saint, ... born infections are common, costly and harmful, but they ... which can be prevented by new and simple// changes. ...
... Chronic Obstructive Pulmonary Disease - including chronic bronchitis and ... blockage of the bronchial tubes. Asthma is a chronic ... resulting in episodes of airflow obstruction, which has been ... death and affects nearly 16 million people in the ...
... in the United States have found that the practice ... the past 14 years. However, they suggested that patients ... Helicobacter Pylori(H.Pylori) infection rather than receiving treatment for the ... more appropriate option// than empiric treatment in patients with ...
... with heart disease has shown that doctors are under-using ... these women even though the medications have been shown ... Though this study did not look at how often ... shown that men and women alike are under-treated for ...
Cached Medicine News:Health News:Adult COPD or asthma could be effectively treated with Xopenex 2Health News:Heart disease in women being under-treated 2
... Utilized for capsulotomies, nucleus ... Formed (bent) cystitomes are angled ... of the lens, providing easier ... while reducing the potential for ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
Medicine Products: